Common Stock, par value $0.001 per share
- Symbol
- TARA
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 2.02, 9.01 · 8-K
Protara Therapeutics, Inc.
TARANASDAQEQUITYCurrent
Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On November 6, 2026, Protara Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2026 in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference.…
Press release in this filing
Protara Therapeutics Announces Third Quarter 2026 Financial Results and Provides a Business Update →Company context
Protara is a clinical-stage biotechnology company committed to advancing transformative therapies for people with cancer and rare diseases. Protara’s portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is evaluating TARA-002 in ongoing clinical trials in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naïve to treatment with Bacillus Calmette-Guérin, as well as a pivotal Phase 2 trial in pediatric patients with LMs. Additionally, Protara is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral support who are otherwise unable to meet their choline needs via oral or enteral routes. For more information, visit www.protaratx.com.
Current securities
Registered securities in this filing
Protara Therapeutics, Inc. · 8-K · Filed 2026-11-06
Disclosure sections
Item 2.02Item 2.02 - Results of Operations
Item 2.02. Results of Operations and Financial Condition.
On November 6, 2026, Protara
Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2026 in the press release
attached hereto as Exhibit 99.1 and incorporated herein by reference.
The information in this Item
2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18
of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section,
nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the
Exchange Act, except as shall be expressly set forth by specific reference in such a filing regardless of any general incorporation language.
Filed exhibits (1)
Exhibit 99.1 Protara Therapeutics Announces Third Quarter 2026 Financial Results and Provides a Business Update Expect to complete enrollment of the BCG-Unresponsive registrational cohort of the ADVANCED-2 trial of TARA-002 in NMIBC by year-end 2026 Enrollment in registrational STARBORN-1 trial now expected to complete in early 1Q’2027; expect to initiate a rolling BLA submission for TARA-002 in LMs in 2H 2027 Completed enrollment of THRIVE-3 Phase 2b dosing cohort evaluating IV Choline Chloride in patients dependent on long-term parenteral support; remain on track to report interim results by year-end 2026 Entered into an asset purchase agreement with Novex Innovations for TARA-002 manufacturing-related assets for $8.75 million Cash, cash equivalents and investments of approximately $143 million as of September 30, 2026, expected to support planned operations into 2028 NEW YORK, November 6, 2026 -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage biotechnology company developing transformative therapies for the treatment of cancer and rare diseases, today announced financial results for the third quarter ended September 30, 2026 and provided a business update. “…
Open exhibit ↗